{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T23:08:23Z","timestamp":1788736103295,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ctrv.2026.103196","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:21:10Z","timestamp":1785194470000},"page":"103196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Vinorelbine and low-dose cyclophosphamide as maintenance therapy in the treatment of Ewing sarcoma rationale for the international INTER-EWING-1 trial for Ewing sarcoma patients"],"prefix":"10.1016","volume":"149","author":[{"given":"Lianne M.","family":"Haveman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa L.","family":"Hjalgrim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Mata","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perrine","family":"Marec-Berard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Laurence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes H.M.","family":"Merks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Valverde","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Berlanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra J.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Luksch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ctrv.2026.103196_bb0005","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.3390\/jcm10081685","article-title":"Ewing sarcoma-diagnosis, treatment, clinical challenges and future perspectives","volume":"10","author":"Z\u00f6llner","year":"2021","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103196_bb0010","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/ijc.33674","article-title":"Comparative international incidenc Ewing sarcoma 1988 to 2012","volume":"149","author":"Spector","year":"2021","journal-title":"Int J Cancer"},{"issue":"31","key":"10.1016\/j.ctrv.2026.103196_bb0015","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.78.2516","article-title":"High-dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk Ewing sarcoma: results of Euro-E.W.I.N.G.99 and Ewing-2008","volume":"36","author":"Whelan","year":"2018","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.ctrv.2026.103196_bb0020","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/1078-0432.CCR-23-1966","article-title":"Zoledronic acid add-on therapy for standard-risk Ewing sarcoma patients in the Ewing 2008R1 trial","volume":"29","author":"Koch","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103196_bb0025","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1200\/JCO.2000.18.17.3108","article-title":"Prognostic factors in Ewing\u2019s tumor of bone: analysis of 975 patients from the European intergroup cooperative Ewing\u2019s sarcoma study group","volume":"18","author":"Cotterill","year":"2000","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103196_bb0030","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/MPH.0b013e31816e22f3","article-title":"Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: surveillance epidemiology and end results data","volume":"30","author":"Esiashvili","year":"2008","journal-title":"J Pediatr Hematol Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103196_bb0035","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/jjco\/hyr033","article-title":"Treatment outcome of Korean patients with localized Ewing sarcoma family oftumors: a single institution experience","volume":"41","author":"Lee","year":"2011","journal-title":"Jpn J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ctrv.2026.103196_bb0040","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2009.22.9864","article-title":"Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial","volume":"28","author":"Ladenstein","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2026.103196_bb0045","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1200\/JCO.21.01942","article-title":"High-dose Treosulfan and Melphalan as consolidation therapy versus standard therapy for high-risk (metastatic) Ewing sarcoma","volume":"40","author":"Koch","year":"2022","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.ctrv.2026.103196_bb0050","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1200\/JCO.2011.41.5703","article-title":"Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the children\u2019s oncology group","volume":"30","author":"Womer","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103196_bb0055","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13063-019-4026-8","article-title":"International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 protocol","volume":"21","author":"Anderton","year":"2020","journal-title":"Trials"},{"issue":"10362","key":"10.1016\/j.ctrv.2026.103196_bb0060","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(22)01790-1","article-title":"Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial","volume":"400","author":"Brennan","year":"2022","journal-title":"Lancet"},{"issue":"34","key":"10.1016\/j.ctrv.2026.103196_bb0065","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1200\/JCO.19.00915","article-title":"High-dose chemotherapy compared with standard chemotherapy and lung radiation in Ewing sarcoma with pulmonary metastases: results of the European Ewing Tumour Working Initiative of National Groups, 99 trial and EWING 2008","volume":"37","author":"Dirksen","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103196_bb0070","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1200\/JCO.2005.05.105","article-title":"Survival after recurrence of Ewing's sarcoma family of tumors","volume":"23","author":"Barker","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103196_bb0075","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/cncr.10192","article-title":"Survival after recurrence of Ewing tumors: the St Jude children's research hospital experience, 1979\u20131999","volume":"94","author":"Rodriguez-Galindo","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2026.103196_bb0080","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/pbc.23040","article-title":"Risk of recurrence and survival after relapse in patients with Ewing sarcoma","volume":"57","author":"Stahl","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"27","key":"10.1016\/j.ctrv.2026.103196_bb0085","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/JCO.2014.59.5256","article-title":"Ewing sarcoma: current management and future approaches through collaboration","volume":"33","author":"Gaspar","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103196_bb0090","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.2147\/OTT.S170585","article-title":"Management of recurrent Ewing sarcoma: challenges and approaches","volume":"27","author":"Van Mater","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ctrv.2026.103196_bb0095","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.trecan.2020.05.007","article-title":"Metronomic maintenance for high-risk pediatric malignancies: one size will not fit all","volume":"6","author":"Andr\u00e9","year":"2020","journal-title":"Trends Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103196_bb0100","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","article-title":"The anti-angiogenic basis of metronomic chemotherapy","volume":"4","author":"Kerbel","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"16","key":"10.1016\/j.ctrv.2026.103196_bb0105","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1200\/JCO-24-02850","article-title":"Maintenance chemotherapy in patients with high-risk rhabdomyosarcoma: long-term survival analysis of the European Paediatric soft tissue sarcoma study group RMS 2005 trial","volume":"43","author":"Bisogno","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103196_bb0110","first-page":"2261","article-title":"Treatment-related mutagenic processes in acute lymphoblastic leukemia","volume":"110","author":"Van der Ham","year":"2025","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103196_bb0115","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1002\/cncr.10600","article-title":"Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma","volume":"94","author":"Casanova","year":"2002","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.ctrv.2026.103196_bb0120","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1016\/j.ejca.2012.04.012","volume":"48","author":"Minard-Colin","year":"2012","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103196_bb0125","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27693","article-title":"SFCE METRO-01 four-drug metronomic regimen phase II trial for pediatric extracranial tumor","volume":"66","author":"Heng-Maillard","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103196_bb0130","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1001\/jamaoncol.2017.0324","article-title":"Metronomic chemotherapy vs best supportive Care in Progressive Pediatric Solid Malignant Tumors: a randomized clinical trial","volume":"3","author":"Pramanik","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103196_bb0135","first-page":"39","article-title":"Maintenance treatment with trofosfamide in patients with primary bone Ewing sarcoma - single center experience","volume":"23","author":"Raciborska","year":"2019","journal-title":"Dev Period Med"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103196_bb0140","first-page":"573","article-title":"Relapse after high-dose therapy in relapsed Ewing\u2019s tumor patients: effects of maintenance chemotherapy in two selected patients?","volume":"26","author":"Laws","year":"2003","journal-title":"Onkologie"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103196_bb0145","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/pbc.24794","article-title":"A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer","volume":"61","author":"Robison","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103196_bb0150","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.ejca.2012.03.022","article-title":"Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma","volume":"48","author":"Schuetze","year":"2012","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103196_bb0155","doi-asserted-by":"crossref","first-page":"6835","DOI":"10.2147\/CMAR.S181087","article-title":"The efficacy and safety of apatinib in Ewing\u2019s sarcoma: a retrospective analysis in one institution","volume":"11","author":"Wang","year":"2018","journal-title":"Cancer Manag Res"},{"issue":"34","key":"10.1016\/j.ctrv.2026.103196_bb0160","first-page":"4534","article-title":"Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sacoma","volume":"29","author":"Juergens","year":"2011","journal-title":"Clin Oncol"},{"issue":"30","key":"10.1016\/j.ctrv.2026.103196_bb0165","first-page":"22","article-title":"Retrospective analysis of outcomes of patients with relapsed, refractory and metastatic sarcomas who have received metronomic chemotherapy","volume":"1","author":"Devadas","year":"2019","journal-title":"Gulf J Oncolog"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103196_bb0170","article-title":"Bevacizumab, with Sorafenib and cyclophosphamide provides clinical benefit for recurrent or refractory osseous sarcomas in children and young adults","volume":"25","author":"Bodea","year":"2022","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103196_bb0175","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31707","article-title":"Results of the Latin American Pediatric Oncology Group (GALOP) trial for patients with metastatic Ewing sarcoma: multicentric study of interval-compressed multiagent and metronomic chemotherapy","volume":"72","author":"Rose","year":"2025","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103196_bb0180","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28508","article-title":"Metro-SMHOP 01: Metronomics combination with cyclophosphamide-etoposide and valproic acid for refractory and relapsing pediatric malignancies","volume":"67","author":"El Kababri","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103196_bb0185","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/S1470-2045(19)30617-5","article-title":"Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-riskrhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Bisogno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103196_bb0190","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/pbc.20682","article-title":"Response to vinorelbine and low-dose cyclophosphamide chemotherapy in two patients with desmoplastic small round cell tumor","volume":"49","author":"Ferrari","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103196_bb0195","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/cncr.20544","article-title":"Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European rhabdomyosarcoma protocol","volume":"101","author":"Casanova","year":"2004","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103196_bb0200","doi-asserted-by":"crossref","first-page":"960","DOI":"10.18632\/oncotarget.358","article-title":"Pilot study of a pediatric metronomic 4-drug regimen","volume":"2","author":"Andr\u00e9","year":"2011","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103196_bb0205","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/pbc.22133","article-title":"Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a children\u2019s oncology group study","volume":"53","author":"Kuttesch","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103196_bb0210","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/pbc.21494","article-title":"Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial","volume":"50","author":"Klingebiel","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103196_bb0215","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/cncr.30411","article-title":"Results of a randomized, prospective clinical trial evaluating metronomic chemotherapy in nonmetastatic patients with high-grade, operable osteosarcomas of the extremities: a report from the Latin American Group of Osteosarcoma Treatment","volume":"123","author":"Senerchia","year":"2017","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.ctrv.2026.103196_bb0220","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1200\/JCO.2014.60.0734","volume":"33","author":"Bielack","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103196_bb0225","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/210198","article-title":"A randomized study on Postrelapse disease-free survival with adjuvant mistletoe versus Oral etoposide in osteosarcoma patients","volume":"2014","author":"Longhi","year":"2014","journal-title":"Evid Based Complement Alternat Med"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103196_bb0230","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-22-2470","article-title":"First-in-maintenance therapy for localized high-grade osteosarcoma: an open-label phase I\/II trial of the anti-PD-L1 antibody ZKAB001","volume":"29","author":"Zhou","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103196_bb0235","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.3390\/cancers15072050","article-title":"Pediatric patients with stage IV rhabdomyosarcoma significantly benefit from long-term maintenance therapy: results of the CWS-IV 2002 and the CWS DOK IV 2004-trials","volume":"15","author":"Tramsen","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"14","key":"10.1016\/j.ctrv.2026.103196_bb0240","article-title":"Oral vinorelbine and continuous low doses of cyclophosphamide in pediatric rhabdomyosarcoma: a real-world study","volume":"3","author":"Lan","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ctrv.2026.103196_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102957","article-title":"Maintenance therapy with trofosfamide, idarubicin and etoposide in patients with rhabdomyosarcoma and other high-risk soft tissue sarcomas (CWS-2007-HR): a multicentre, open-label, randomised controlled phase 3 trial","volume":"78","author":"Koscielniak","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103196_bb0250","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30707","article-title":"Significance of fusion status, Oberlin risk factors, local and maintenance treatment in pediatric and adolescent patients with metastatic rhabdomyosarcoma: data of the European Soft Tissue Sarcoma Registry SoTiSaR","volume":"71","author":"Heinz","year":"2024","journal-title":"Pediatr Blood Cancer"},{"issue":"2020","key":"10.1016\/j.ctrv.2026.103196_bb0255","article-title":"Long-term follow-up of a randomized study of Oral etoposide versus Viscum album Fermentatum Pini as maintenance therapy in osteosarcoma patients in complete surgical remission after second relapse","volume":"26","author":"Longhi","year":"2020","journal-title":"Sarcoma"},{"key":"10.1016\/j.ctrv.2026.103196_bb0260","doi-asserted-by":"crossref","unstructured":"Laurence V, Jehanno N, Dureau S, Mous L, Claude L, Ballet S, Pierron G, Gaspar N, Brahmi M, Valentin T, Revon-Rivi\u00e8re G, Lervat C, Probert J, Entz-Werle N, Mansuy L, Plantaz D, Rios M, Saumet L, V\u00e9rit\u00e9 C, Castex MP, Thebaud E, Cassou-Mounat T, Plissonnier AS, Dieppedale J, Delattre O, Legrier ME, Marec- B\u00e9rard P, Gouin F, Berlanga P, Cordero C, Surdez D, Corradini N. Interest of a sequential multimodal approach for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma: results of the French prospective CombinaiR3 phase II trial. Br J Cancer. 2026 Jan;134(2):279-288. doi: 10.1038\/s41416-025-03263-3. Epub 2025 Nov 17. PMID: 41249450; PMCID: PMC12820225.Laurence V, Jehanno N, Dureau S, Mous L, Claude L, Ballet S, Pierron G, Gaspar N, Brahmi M, Valentin T, Revon-Rivi\u00e8re G, Lervat C, Probert J, Entz-Werle N, Mansuy L, Plantaz D, Rios M, Saumet L, V\u00e9rit\u00e9 C, Castex MP, Thebaud E, 2026.","DOI":"10.1038\/s41416-025-03263-3"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103196_bb0265","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41416-025-03263-3","article-title":"Interest of a sequential multimodal approach for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma: results of the French prospective CombinaiR3 phase II trial","volume":"134","author":"Cassou-Mounat","year":"2026","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103196_bb0270","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/bjc.2017.252","article-title":"GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS)","volume":"117","author":"Mora","year":"2017","journal-title":"Br J Cancer"},{"issue":"20","key":"10.1016\/j.ctrv.2026.103196_bb0275","doi-asserted-by":"crossref","first-page":"6454","DOI":"10.1158\/1078-0432.CCR-09-0970","article-title":"Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer","volume":"15","author":"Briasoulis","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103196_bb0280","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1517\/14740338.4.5.915","article-title":"Oral versus intravenous vinorelbine: clinical safety profile","volume":"4","author":"Gebbia","year":"2005","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103196_bb0285","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/cam4.3712","article-title":"Systematic review of phase-I\/II trials enrolling refractory and recurrent Ewing sarcoma: actual knowledge and future directions to optimize the research","volume":"10","author":"Felix","year":"2021","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103196_bb0290","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/CCO.0000000000001048","article-title":"Emerging therapies in Ewing sarcoma","volume":"36","author":"Strauss","year":"2024","journal-title":"Curr Opin Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T22:28:58Z","timestamp":1788733738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226001106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":58,"alternative-id":["S0305737226001106"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103196","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vinorelbine and low-dose cyclophosphamide as maintenance therapy in the treatment of Ewing sarcoma rationale for the international INTER-EWING-1 trial for Ewing sarcoma patients","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103196","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103196"}}